A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide-Reference-Cited by-同舟云学术

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide

Published:2021-11-08 Issue:2 Volume:24 Page:302-311
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Tham Lai San¹^ORCID,Pantalone Kevin M.²^ORCID,Dungan Kathleen³^ORCID,Munir Kashif⁴^ORCID,Tang Cheng Cai¹,Konig Manige⁵^ORCID,Kwan Anita Y. M.⁵

Affiliation:

1. Lilly Centre for Clinical Pharmacology Singapore

2. Department of Endocrinology Cleveland Clinic Cleveland Ohio USA

3. Division of Endocrinology, Diabetes and Metabolism The Ohio State University Columbus Ohio USA

4. Division of Endocrinology, Diabetes and Nutrition University of Maryland School of Medicine Baltimore Maryland USA

5. Eli Lilly and Company Indianapolis Indiana USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14582

Reference34 articles.

1. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis

2. FDA. Ozempic (semaglutide) US Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf. Accessed February 16 2021.

3. FDA. Trulicity (dulaglutide) US Prescribing Information.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf. Accessed February 16 2021.

4. Review article: a comparison of glucagon-like peptides 1 and 2

5. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model;CPT: Pharmacometrics & Systems Pharmacology;2024-06-12

2. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide;Current Medical Research and Opinion;2024-03-12

3. Current and novel treatment options for obstructive sleep apnoea;ERJ Open Research;2022-04

4. Indirect treatment comparisons: Choosing the right tool for the job;Diabetes, Obesity and Metabolism;2022-02-21

5. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting;Annals of Translational Medicine;2022-02